03:58 PM EST, 12/17/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.)

Tenaya Therapeutics ( TNYA ) shares plunged nearly 51% in recent trading on Tuesday after initial data for this gene therapy study indicated a manageable safety profile with isolated elevations in liver enzymes of the first three dosed patients.

The company said Tuesday that preliminary data from the first cohort in a phase 1b/2 trial showed that its TN-201 gene therapy was well tolerated, with no cardiac toxicities or severe adverse effects.

TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy, a condition caused by insufficient levels of myosin-binding protein C, the company said.

Tenaya said the initial results demonstrated "readily detectable vector DNA in the heart, evidence of transgene RNA expression, and increasing TN-201 mRNA and MyBP-C protein levels over time."

Price: 1.42, Change: -1.46, Percent Change: -50.76